May 20, 2022
An end-of-week review of retina news and stories from May 13 to May 20.
May 11, 2022
Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
May 03, 2022
Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
April 30, 2022
A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.
April 20, 2022
A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.
April 01, 2022
Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.
March 31, 2022
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
November 02, 2021
Underlying autoimmune disease alters uveitis therapy.
October 26, 2021
XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.
